Company intelligence / Profile preview
KLSMC Stem Cells
Kuala Lumpur, Kuala Lumpur, Malaysiaklsmc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Clinical studies have shown that intra-articular injection of a patient’s own peripheral blood stem cells after subchondral drilling surgery can regenerate hyaline cartilage in the knee. A multicenter Phase 2 trial demonstrated safety and efficacy compared to standard treatment with hyaluronic acid injections and physiotherapy. The company plans to initiate a US FDA Phase 3 trial.
- Therapeutic areas
- Rheumatology
- Modalities
- Stem cell therapyCell therapyAutologous peripheral blood stem cells
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bioeconomy Corporation Malaysia ("BioNexus" status)Universiti Malaysia as investor/supporter
Beyond the preview
Go deeper on KLSMC Stem Cells.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLSMC Stem Cells.